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ABSTRACT
INTRODUCTION: Despite centuries of research and clinical work, the diagnosis of diabetes was still treated 
as a quick death sentence at the beginning of the 20th century. Unfortunately, the number of patients with 
diabetes is increasing every year. Type 2 diabetes is increasingly common among young people: children and 
adolescents. The article discusses the type of diabetes and the importance of rapid diagnosis and manage-
ment. Type 1 diabetes, type 2 diabetes, latent autoimmune diabetes in adults, monogenic diabetes, gesta-
tional diabetes were analysed. Life-threatening conditions resulting from complications of diabetes including 
diabetic ketoacidosis, hyperglycaemic-hyperosmolar state, hypoglycaemia, lactic acidosis were discussed, 
and the first-line emergency treatment were analysed. The life-threatening complications of diabetes and 
rescue procedures in these conditions were discussed in detail.
CONCLUSIONS: Due to the frequency of life-threatening complications, diabetes is a heavy burden on the 
medical staff. Adequate diagnosis and implementation of appropriate treatment significantly improve the 
patient’s condition.
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INTRODUCTION 
Diabetes has been a disease known to people for 
at least five thousand years. The oldest preserved 
description of diabetes, today called type 1 diabetes, 
is contained in the Egyptian papyrus dating back to 
around 1550 BC. Areteus of Cappadocia was the 
first physician to use the term “diabetes” in his work 
“Acute and chronic diseases” [1]. 
Despite centuries of research and clinical work, 
the diagnosis of diabetes was still treated as a quick 
death sentence at the beginning of the 20th cen-
tury. The prognosis for diabetic patients improved 
after the introduction of insulin to medicine in 1922, 
followed by oral anti-diabetic drugs.
Unfortunately, the number of patients with di-
abetes is increasing every year. It is estimated that 
in 2014, more than 422 million adults worldwide 
suffered from diabetes. In the last decade, the 
prevalence of diabetes has increased faster in low- 
and middle-income countries than in high-income 
countries. In 2012, diabetes caused 1.5 million 
deaths. Higher than optimal blood glucose levels 
caused an additional 2.2 million deaths, increasing 
the risk of cardiovascular and other diseases [2]. 
Diabetes is an increasingly common disease. In 
Poland, it affects nearly 3 million people, 80% of 
whom are patients with type 2 diabetes. Over 5 mil-
lion Poles have a pre-diagnosed pre-diabetes condi-
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tion. Unhealthy dietary habits and lack of physical 
activity cause that the number of patients is con-
stantly growing. Unfortunately, type 2 diabetes is 
increasingly common among young people: children 
and adolescents. Diabetes is the first non-infectious 
disease recognized more than 10 years ago by the 
United Nations as an epidemic of the XXI century [3].
TYPES Of DIABETES
Type 1 diabetes 
Contrary to popular belief, type 1 diabetes is not 
a child-age disease. It occurs at all ages, in people of 
all races [2]. Depends on the rate of β cell loss. Rapid 
exhaustion of β cell secretion reserves in children 
and adolescents is the cause of sudden onset of the 
disease (the first symptoms of which are acidosis 
and ketosis) and unstable course of diabetes mellitus 
with tendency to glucose fluctuations from hyperg-
lycaemia to hypoglycaemic coma. The fluctuating 
course of diabetes accelerates the development of 
chronic complications, which may appear as early 
as from the 5th year of the disease’s duration [3]. 
Latent Autoimmune Diabetes in Adults
The definition of type 1 diabetes with autoimmune 
aetiology includes autoregressive, slowly developing 
diabetes. Latent Autoimmune Diabetes in Adults 
(LADA) is a late manifestation of autoimmune diabe-
tes in adults, most commonly diagnosed in patients 
over 35 years of age, characterized by clinical insulin 
dependence in the first months after diagnosis [4]. 
Type LADA belongs to type 1 diabetes with a slow 
progressing autoimmune process of β-cell destruc-
tion. This subtype of diabetes affects 5–10 % of 
people with diabetes diagnosed as type 2 diabetes 
after the age of 35. Clinical symptoms in LADA 
type diabetes do not always allow to make the final 
diagnosis, causing diagnostic difficulties in differen-
tiation with type 2 diabetes [5]. 
For a reliable diagnosis of LADA diabetes, the 
presence of antibodies typical of type 1 diabetes, 
in particular, anti-GAD65, and/or a low C peptide 
concentration is necessary [6, 7]. 
In adults, at the time of diagnosis of type 1 di-
abetes, the following features are most common:
 – the age of 20–50 years;
 – slim figure;
 – no diabetes in the family;
 – increased clinical symptoms of hyperglycaemia 
(polyuria, increased thirst);
 – ketoacidosis or ketonuria;
 – significant (5–10 kg) unintentional weight loss 
within a few weeks;
 – normal urine sediment pattern;
 – a moderately elevated HbA1c value at the time 
of diagnosis.
Once the glycaemia is stabilized in these patients, 
lipid metabolism and arterial blood pressure are usu-
ally normal. It should be remembered that routine au-
toimmune tests and serum C-peptide testing are not 
necessary to diagnose type 1 diabetes. The diagno-
sis of classical symptoms of hyperglycaemia and the 
above-mentioned features, as well as the presence of 
ketonuria, justify the diagnosis of type 1 diabetes mel-
litus and consequently the initiation of insulin thera-
py. In doubtful cases, the determination of islet cell 
antibody (ICA) and autoantibodies to glutamic acid 
decarboxylase (anti-GAD) makes it very easy to deter-
mine the correct diagnosis [8]. Even a slight increase 
in any of the above antibody parameters suggests an 
autoimmune background of hyperglycaemia. C-pep-
tide assessment, especially only in fasting conditions, 
is of no significance for differentiation of diabetes 
types or prognosis of treatment course [1].
Monogenic diabetes
It is conditioned by the mutation of a single gene, 
leading in most cases to a defect in insulin secretion 
and represents 1–2% of all cases of diabetes. The fi-
nal diagnosis is established on the basis of the result 
of a genetic test [9]. The importance of diagnosing 
monogenic diabetes results from the possibility of 
family prognosis [10]. The most common forms of 
monogenic diabetes are Maturity Onset Diabetes 
of the Young (MODY), mitochondrial diabetes and 
neonatal diabetes [11]. 
Type 2 diabetes 
Diabetes type 2 is a complex and multi-factorial dis-
ease that occurs through the interaction of genetic 
and environmental factors leading to two major 
overlapping pathologies: a defect in insulin secretion 
and a reduction in insulin sensitivity in peripheral 
tissues [12].
The development of the disease begins with 
a gradual increase in insulin resistance — a state 
of impaired peripheral tissue response to insulin; it 
depends on both genetic and environmental condi-
tions — peripheral tissues, which may occur several 
years before the onset of fully symptomatic diabe-
tes. Elevated glucose levels are observed when this 
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compensatory ability of β cells becomes depleted 
and there is a relative deficiency of insulin.
The most characteristic feature of patients with 
type 2 diabetes is overweight and obesity, as well as: 
age above 50 years of age, history of diabetes in the 
family; low physical activity; recurrent infection (es-
pecially of the skin and urinary tract) in the history; 
features of glucose intolerance observed in the past; 
abdominal obesity; other features of the metabolic 
syndrome: hypertension, lipid disorders; existing vas-
cular complications (heart attack, stroke, retinopa-
thy, nephropathy); moderately elevated, high or very 
high HbA1c value at the time of diagnosis [13–15].
Subjective symptoms are non-specific and varied, 
related to the type of diabetes and the dynamics 
of the disease. More than half of the cases of type 
2 diabetes are asymptomatic, but also lead to the 
development of chronic complications, especially 
cardiovascular ones, which are the main cause of 
death in these patients [4]. Clinically, in patients 
with type 2 diabetes, good glycaemic response to 
increased physical activity and dietary restrictions, as 
well as to oral drugs, is observed in the early stages 
of the disease [16, 17].
Gestational diabetes
Gestational diabetes mellitus (GDM) is diagnosed as 
having hyperglycaemia during pregnancy in a wom-
an who has not yet had diabetes mellitus, with 
values corresponding to the diagnosis of diabetes 
mellitus or any of the conditions of glucose intoler-
ance [17]. During pregnancy, especially in the 2nd 
and 3rd trimesters, there is a physiological decrease 
in insulin sensitivity and a worsening of glucose 
tolerance [18].
The groups of increased risk of developing dia-
betes during pregnancy are: elderly women; obese 
women; women with glycosuria (presence of glu-
cose in urine) found in two accidentally diagnosed 
tests during pregnancy; pregnant women with 
hydramnios; women with glucose intolerance in 
history; history of birth of a newborn with body-
weight > 4.5 kg; in family history — first-degree 
relatives diabetes mellitus.
Life-threatening conditions resulting from 
complications of diabetes mellitus
Diabetic ketoacidosis
Diabetic ketoacidosis is an acute complication of 
diabetes, which is a direct life-threatening condition. 
Untreated ketoacidosis can lead to diabetic coma 
and even death. The main causes of diabetic ke-
toacidosis include discontinuation of insulin therapy 
or making some mistakes, e.g. inappropriate doses; 
late diagnosis of type 1 diabetes; alcohol abuse; 
acute inflammations (e.g. bacterial, viral, fungal in-
fections); and pregnancy. The occurrence of ketoac-
idosis may be directly life-threatening. The most 
severe (although rare) complication may be cerebral 
oedema, which is more common in children. In addi-
tion, hypovolemic shock and acute renal failure may 
also occur. The cause of the disorders is a significant 
deficiency of insulin leading to hyperglycaemia, re-
duced sensitivity to insulin in conditions of systemic 
infection or an increase in the concentration of hy-
perglycaemic hormones. Insulin deficiency leads to 
the release of free fatty acids and their subsequent 
oxidation in the liver to ketone compounds. Glyco-
suria and hyperglycaemia lead to osmotic diuresis, 
dehydration and electrolyte disorders.
In case of diabetic ketoacidosis, the patient may 
present the following symptoms: abdominal pain, 
which is most common in children, headaches, ex-
cessive fatigue and general weakness, deepened 
and accelerated breathing (the so-called Kussmaul 
breathing); specific mouth and urine acetone smell 
similar to the smell of rotten apples as well as con-
sciousness disturbances. Symptoms of ketoacidosis 
may be similar to those of poisoning or gastroin-
testinal infections. If elevated blood glucose levels 
persist for a prolonged period, especially if vomiting 
occurs, the presence of acetone in urine or blood 
ketone levels should be checked by means of special 
test strips.
When differentiating between diabetic ketoaci-
dosis, one should consider disorders such as “acute 
abdomen”, hyperglycaemic conditions with differ-
ent pathogenesis, including hyperglycaemic and 
hyperosmolar conditions, as well as coma of other 
origins such as hypoglycaemic, uremic, hepatic, cer-
ebral and resulting from poisoning. 
Emergency management in diabetic ketoacidosis 
is based on securing basic vital functions according 
to ABCDE scheme. The next element is the supple-
mentation of fluid deficits in the vascular bed. In or-
der to do this, it is necessary to start with 1L infusion 
of isotonic solution 0.9% NaCl within the first hour 
of treatment. The remaining deficit, which usually 
ranges from 5 to 10 L, should be corrected within 
6 to 12 hours. The administration of short-acting 
insulin in a single dose of 8–10 units is another 
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step in the management. A continuous infusion at 
0.1 unit/kg body weight per hour is then adminis-
tered. The dose should be adjusted individually to 
lowered glycaemia with a rate of 50–70 mg/dL/hr. If 
glycaemia is lowered below 200 mg/dL, an infusion 
of 5% glucose solution should be implemented. 
The dose of potassium used should be 20 mEq of 
potassium chloride per litre of fluid for patients with 
normokaliemia and 40 mEq/L for patients with hy-
pokalemia.
Hyperglycaemic-hyperosmolar state — HHS 
Hyperglycaemic-hyperosmolar state is a metabolic 
disorder that occurs with significant dehydration 
of the body as a result of disturbed mechanisms 
regulating thirst or limited fluid intake. The hyperg-
lycaemic-hyperosmolar state results from the symp-
toms of uncontrolled or untreated diabetes. Blood 
glucose increases first, usually exceeds 600 mg/dL 
(33.3 mmol/L) [19]. As a consequence, osmotic diu-
resis, systemic electrolyte deficiencies and dehydra-
tion occur. Then the hyperosmolarity of the serum, 
usually above 350 mmol/L, occurs with simultane-
ously observed symptoms of ketoacidosis and met-
abolic acidosis.
The most common causes of hyperglycaemic-hy-
perosmolar state include pneumonia, cardiovascu-
lar disorders, kidney failure, urinary tract infection, 
acute pancreatitis or excessive alcohol consumption. 
It may also result from iatrogenic complications, 
including diuretics treatment or peritoneal dialysis. 
A patient with hyperglycaemic-hyperosmolar 
state requires treatment in an intensive care unit. 
The symptoms of HHS usually develop gradually 
— within a few days, contrary to diabetic ketoaci-
dosis — where the symptoms develop within a few 
hours [20]. The symptoms associated with signifi-
cant dehydration appear: dry mucosa, loss of skin 
elasticity, increased thirst. In addition, one observes 
tachypnea well as tachycardia, reduced blood pres-
sure and headaches. Depending on the severity of 
developed HHS, there are variously intense con-
sciousness disorders, including coma. Sometimes 
seizures, paresis of extremities, visual disturbances 
can be observed. 
The differential diagnosis of hyperglycaemic-hy-
perosmolar state should include acute disorders of 
the central nervous system, coma resulting from 
poisoning or coma of other origins, including hy-
poglycaemic, liver, brain, uremic or ketone disorders 
[21, 22]. 
The treatment is multidirectional, the most im-
portant is hydration, intravenous insulin administra-
tion, infection control and treatment of coexisting 
diseases. However, from the point of view of emer-
gency medicine, management should include restor-
ing normal fluid volume and compensating for elec-
trolyte deficiencies [23]. For this purpose, consider 
the infusion of 1–2 L of 0.9% physiological NaCl 
solution within the first hour of treatment. It is worth 
remembering that half of the fluid deficit should be 
supplemented within 12 hours. Another aspect is 
potassium deficiency compensation. The dose of 
potassium should be 20 mEq of potassium chloride 
per litre of fluid for patients with normokalemia and 
40 mEq/L for patients with hypokalemia. Insulin 
therapy is another element of emergency manage-
ment. Treatment should begin with a single dose 
of 8–10 units of intravenous short-term insulin, fol-
lowed by an infusion at 0.1 unit/kg body weight 
per hour. The dose should be adjusted individually 
to reduce glycaemia at a rate of 50–70 mg/dL/h. If 
glycaemia is reduced below 200 mg/dL, an infusion 
of 5% glucose solution should be implemented [24]. 
Hypoglycaemia
Hypoglycaemia is the most common complication 
in diabetic patients treated with insulin or oral hy-
poglycaemic drugs [25]. Hypoglycaemia may also 
occur, apart from the two factors mentioned above, 
as a result of a delayed meal or glucose products 
intake, physical activity, excessive calorie loss, alcohol 
consumption or excessive glucose consumption and 
impairment of its use in gluconeogenesis [26]. An 
American Diabetes Association (ADA) working party 
has attempted a comprehensive definition [27]. Ac-
cording to this association, “severe hypoglycaemia” 
is defined as an episode requiring the assistance 
of another person to administer treatment, “docu-
mented symptomatic hypoglycaemia” as the pres-
ence of common symptoms of hypoglycaemia with 
a measured plasma glucose < 3.9 mmol/L, “prob-
able symptomatic hypoglycaemia” as self-reported 
symptoms not verified by a glucose measurement 
and “relative hypoglycaemia” as the presence of 
symptoms with a plasma glucose > 3.9 mmol/L.
While in the case of hyperglycaemia it takes a rel-
atively long time for the patient to develop con-
sciousness disorders, in the case of hypoglycaemia 
these changes occur quickly. In most cases, a patient 
can feel that his blood glucose level decreases, but 
in case of adrenergic reactions, increased expression 
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of glucotransporter genes or neuropathy — the feel-
ing of increasing symptoms of hypoglycaemia may 
be significantly impaired [27]. 
Depending on the severity of the hypoglycaemia, 
we can expect an adequate patient’s condition [28, 29]. 
A detailed summary of the symptoms of hypoglycae-
mia by blood glucose level is given in Table 1 [30]. 
During the hypoglycaemic state, the body begins 
to release so-called counterregulatory hormones, 
which are intended to counteract the growing hypo-
glycaemia. These hormones include catecholamine, 
glucagon, growth hormone and cortisol [31–33]. 
The causes of hypoglycaemia could be numer-
ous. However, in the case of diabetics, a decrease 
in blood glucose level is most often a consequence 
of overdose of insulin or sulfonylurea derivatives - 
a stimulant of its secretion [34]. 
During differentiation, many potential patholo-
gies and causes of hypoglycaemia should be con-
sidered, including epileptic seizure, stroke, alcohol 
abuse, depression, psychosis, dehydration and elec-
trolyte disorders, liver or kidney failure or overdose 
of sympatheticomimetric drugs.
The management of hypoglycaemia in a patient 
who is conscious and presents symptoms of mild 
to moderate hypoglycaemia should be directed to 
oral administration of simple sugars first and then 
complex sugars which will be released longer. In 
case of unconscious patients, in addition to pro-
tection of the airway, monitoring and intravenous 
access, intravenous glucose 20% / 5% at a dose of 
0.2 g/kg body weight should be administered intra-
venously until a blood concentration of 100 mg/dL is 
achieved. If intravenous access is not available, 1 mg 
of glucagon should be administered intramuscularly 
(Fig. 1), to increase the release of glucose from the 
liver. It should be remembered, however, that the 
glucagon’s action is limited or completely eliminated 
in case of liver tissue damage, prolonged hunger 
strike or alcohol abuse [35]. In the latter two cases, 
an additional 100 mg of thiamine should be consid-
ered, and in the case of prolonged hypoglycaemia, 
hydrocortisone may be necessary to counteract ad-
renal insufficiency. Regardless of whether we lead to 
euglycemia or not, the patient should be transport-
ed to the hospital.
Lactic acidosis
Lactic acidosis, besides ketoacidosis, diabetic hyper-
osmolar syndrome or hypoglycaemia is one of the 
acute complications of diabetes. It occurs as a result 
of intensification of anaerobic glucose metabolism. 
Although it is rare, it is characterized by a high mor-
tality rate of 25–50%. 
Lactic Acidosis is not a specific complication only 
for diabetes. There are many reasons for this condi-
tion. This condition is characterized by an increase in 
blood lactate levels above 5 mmol/L and a simulta-
neous decrease in pH below 7.35. It develops mainly 
in type 2 diabetes as a result of biguanide treatment 
and does not take into account contraindications 
— especially renal failure — and tissue hypoxemia 
due to advanced lung diseases or atherosclerosis. In 
type 1 diabetes, especially when there are renal 
failure and microangiopathy, lactate acidosis may 
be a complication of severe ketoacidosis with high 
dehydration and shock symptoms. Currently, due to 
the cause of lactate acidosis, it is divided into type 
A and type B. Type A is acidosis formed in anaerobic 
conditions as a result of heart failure, respiratory 
failure or shock including hypovolemic, cardiogenic 
or septic shock. In the case of type B lactate acidosis, 
it is formed independently of tissue hypoxia and oc-
curs as a result of liver diseases — which metabolize 
lactic acid to pyruvic acid, kidney diseases — which 
excrete lactic acid along with urine, as well as may 
Table 1. Symptoms of hypoglycaemia
Blood glucose level Symptoms
Mild 
hypoglycaemia
Hunger, sweat, pale skin, anxiety, 
tachycardia, paraesthesia
Moderate 
hypoglycaemia
Headaches, drowsiness, blurred 
vision, concentration disorders, 
aggressive behaviour
Severe 
hypoglycaemia
Hyperventilation, paresis, tonic and 
clonic seizures, confusion and then 
a loss of consciousness, bilateral 
symptom of Babinski, initially increased 
reflexes disappear completely and 
muscles become flaccid
fIGURE 1. A pre-filled syringe with a glucagon
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be associated with severe complications of diabetes, 
including ketoacidosis, or may be the result of im-
proper use of metformin, abuse of methyl or ethyl 
alcohol or high doses of salicylates [36]. 
In diabetes, lactate acidosis concerns mainly pa-
tients treated with metformin. The term Metform-
in-Associated Lactic Acidosis (MALA) refers to any 
case of lactate acidosis that has developed in meth-
amphetamine treated patients [37]. It is noteworthy 
that MALA occurs when metformin is accumulated 
in the body under the influence of triggering factors, 
including tissue hypoxemia and renal failure [38]. 
The exact mechanism, as well as the role of met-
formin in MALA formation, is not finally explained. 
Lactic acid is the final product of anaerobic glucose 
metabolism and occurs mainly in skeletal muscles 
and erythrocytes. The lactate  is then transported to 
the liver, where it is oxidised to pyruvate and finally 
converted by gluconeogenesis into glucose in the 
so-called Cori cycle [39] (Fig. 2). Inhibition of mito-
chondrial chain and decrease in cellular production 
of ATP reduces the level of hepatic gluconeogenesis 
and causes increased concentration of lactic acid, 
which is a specific substrate of retained gluconeo-
genesis. Increased lactic acid levels may also increase 
the transition from aerobic to anaerobic metabolism 
[40]. Lactic acid accumulated in the serum in this 
way is a consequence of the occurrence of acidosis.
During an in-depth medical history the patient 
usually complains about gastrointestinal problems 
such as nausea, vomiting, abdominal pain or diar-
rhoea. Clinical examination shows signs of dehydra-
tion and exhaustion. Kussmaul’s breathing (deep 
and fast), thready and rapid pulse and reduced 
blood pressure are observed. As a result of the 
above symptoms, there is a reduced cardiac index 
and hypotension, which manifests itself in the form 
of disorders of consciousness and circulatory failure 
leading to shock, coma or death. Clinical symptoms 
may resemble myocardial infarction, heavy bleeding 
or pneumonia, as they are the specific initiators of 
lactate acidosis. 
In the differential diagnosis it is worth to take 
into account other aetiologies of acidosis, including 
ketoacidosis or hyperglycaemic-hyperosmolar acido-
sis. In the case of patients in coma, other causes of 
coma, including ketones, hypoglycaemic, cerebral, 
hepatic or toxic coma, should be considered [41–43]. 
Treatment consists primarily in causative treat-
ment (withdrawal of the drug in case of suspicion 
of its correlation with lactate acidosis [40]) and an-
ti-shock management, including: oxygen therapy, 
hydration, intravenous infusion of catecholamines, 
or reduction of hypoglycaemia and acidosis by infu-
sion of insulin at a rate of 0.1 unit/kg body weight 
per hour in an appropriate combination with 5% 
glucose solution. In exceptional cases — at pH be-
low 7.0 — sodium bicarbonate may also be con-
sidered — however, it should be noted that in such 
a case the patient should be properly ventilated, 
because although sodium bicarbonate reduces res-
piratory acidosis, in case of inadequate ventilation 
the patient may exacerbate intracellular acidosis. 
CONCLUSIONS
Due to the frequency of life-threatening complica-
tions, diabetes is a heavy burden for the medical 
staff. Adequate diagnosis and implementation of 
appropriate treatment significantly improve the pa-
tient’s condition.
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